CJC-1295 Pharmacokinetics: How This GH Secretagogue Is Absorbed, Distributed, Metabolized, and Eliminated

How CJC-1295 Works: Mechanism of Action

CJC-1295 is a 30-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) that binds to the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, triggering pulsatile GH secretion. The peptide retains the bioactive core of human GHRH(1-29) but includes four amino acid substitutions at positions 2, 8, 15, and 27 that confer resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage 1.

The DAC Bioconjugation Strategy

What separates CJC-1295 DAC from other GHRH analogs is its reactive chemical moiety, a maleimidopropionic acid linker, that forms a covalent bond with Cys34 on circulating serum albumin within minutes of subcutaneous injection. This albumin conjugation is the pharmacokinetic engine of the drug. Because albumin has a plasma half-life of roughly 19 to 21 days, the peptide effectively piggybacks on albumin recycling through the neonatal Fc receptor (FcRn) pathway 2.

Receptor-Level Signaling

Once bound to GHRH-R, CJC-1295 activates the Gs-adenylyl cyclase-cAMP-PKA cascade inside somatotroph cells, resulting in GH gene transcription and vesicular GH release. The pulsatile pattern of GH release is preserved because the peptide amplifies endogenous GHRH pulses rather than producing a continuous, non-physiologic GH spike 3. This distinguishes CJC-1295 from exogenous recombinant GH, which suppresses the hypothalamic-pituitary feedback axis when administered at supraphysiologic doses.

A single 60 mcg/kg subcutaneous dose of CJC-1295 DAC produced a mean 2- to 10-fold increase in GH concentration that persisted for up to 6 days, and a 1.5- to 3-fold IGF-1 increase lasting 9 to 11 days in the Teichman trial (N=33) 1.

Absorption

CJC-1295 is administered exclusively by subcutaneous injection. No oral formulation exists, and the peptide would be rapidly degraded by gastrointestinal proteases if swallowed.

Subcutaneous Depot Kinetics

After subcutaneous injection, CJC-1295 diffuses from the injection depot into surrounding interstitial fluid. Small peptides (molecular weight ~3,367 Da for the unconjugated form) enter the bloodstream primarily through capillary absorption rather than lymphatic drainage. Time to peak plasma concentration (Tmax) has not been formally reported in published human PK studies, but GH response data suggest rapid absorption: measurable GH elevations appear within 15 to 30 minutes of injection, peaking at 1 to 4 hours 1.

Bioavailability Considerations

Formal absolute bioavailability (F%) for CJC-1295 has not been published in peer-reviewed literature. Subcutaneous peptides of similar molecular weight (e.g., GHRH analogs, tesamorelin) typically show bioavailability in the range of 60 to 80% 4. Injection site (abdomen vs. Thigh) and injection technique may influence absorption speed, though no comparative site data are available for CJC-1295 specifically.

The DAC variant reaches near-complete albumin conjugation quickly. In vitro incubation with human serum shows >90% conjugation within 15 minutes, suggesting the reactive maleimide group binds albumin almost immediately upon reaching the bloodstream 1.

Distribution

Albumin-Bound (DAC) Variant

Once the DAC group covalently binds serum albumin, CJC-1295 distributes wherever albumin distributes. This means the peptide-albumin complex largely remains in the intravascular and interstitial compartments. Albumin has a volume of distribution (Vd) of approximately 0.3 to 0.5 L/kg in healthy adults, and the CJC-1295-albumin conjugate is expected to follow a similar pattern 5.

Tissue Access and Receptor Occupancy

The relevant target tissue is the anterior pituitary. Albumin-bound CJC-1295 accesses pituitary somatotrophs via fenestrated capillaries in the hypothalamic-hypophyseal portal system. Because this capillary bed is highly permeable to plasma proteins, albumin conjugation does not prevent receptor access. The prolonged circulation time means continuous low-level GHRH-R stimulation, amplifying each endogenous GHRH pulse over days rather than minutes.

No-DAC Variant Distribution

The no-DAC (modified GRF 1-29) variant distributes rapidly as a free peptide. Its small size permits wide tissue distribution, but without albumin binding, the peptide is cleared quickly. Plasma concentrations drop below pharmacologically active levels within 30 to 60 minutes.

Metabolism

CJC-1295 metabolism occurs through enzymatic proteolysis, the same pathway that degrades all endogenous and exogenous peptides.

Engineered DPP-IV Resistance

Native GHRH(1-44) is cleaved within minutes by DPP-IV at the Tyr1-Ala2 bond, producing the inactive fragment GHRH(3-44). CJC-1295 incorporates a D-Ala2 substitution that blocks DPP-IV access to this cleavage site. The Gln8Ala, Ala15Leu, and Ala27Leu substitutions provide additional resistance to other serum endopeptidases 1.

Albumin-Mediated Protection

Beyond DPP-IV resistance, the covalent albumin bond physically shields much of the peptide backbone from protease attack. The peptide-albumin conjugate is recycled through FcRn-mediated endosomal salvage in vascular endothelial cells, a process that returns albumin (and its CJC-1295 cargo) to circulation rather than routing it to lysosomal degradation 2.

Metabolic Clearance Pathway

Eventually, the albumin-CJC-1295 complex is internalized by hepatocytes and endothelial cells and directed to lysosomes. Inside the lysosome, the peptide bond and the maleimide linker are cleaved, releasing small peptide fragments and modified amino acids. These fragments have no known pharmacologic activity. The no-DAC variant follows the same proteolytic fate but reaches it within minutes instead of days.

No cytochrome P450 involvement has been identified for CJC-1295 metabolism. Peptides of this size are not substrates for CYP enzymes, which means conventional drug-drug interactions at the CYP level are unlikely 6.

Elimination

Terminal Half-Life

The DAC variant has a reported terminal half-life of 5.8 to 8 days based on GH and IGF-1 pharmacodynamic response data from Teichman et al. 1. True pharmacokinetic half-life (measured by plasma peptide concentration rather than downstream biomarker response) has not been published for CJC-1295 in humans. This distinction matters: pharmacodynamic half-life reflects both drug elimination and the duration of biological effect, which may persist after the drug itself is cleared.

Renal Clearance

Small peptide fragments produced by proteolysis are filtered by the glomerulus. The intact albumin-CJC-1295 conjugate (~70 kDa) is too large for glomerular filtration, so renal elimination applies only to degradation products. Patients with significant renal impairment may clear these fragments more slowly, though no dose-adjustment data are available.

Dose Proportionality

In the Teichman trial, GH and IGF-1 responses showed dose-dependent increases across 30, 60, and 125 mcg/kg single-dose cohorts. The 60 mcg/kg dose produced IGF-1 elevations lasting 9 to 11 days, while the 30 mcg/kg dose produced shorter but still multi-day responses 1.

Steady-State Considerations

Weekly dosing of CJC-1295 DAC at 30 or 60 mcg/kg over four weeks produced sustained IGF-1 elevations without excessive accumulation, though trough GH levels did increase with repeated dosing. The Teichman group reported mean IGF-1 remained 1.5- to 3-fold above baseline throughout the dosing period, with no evidence of tachyphylaxis (receptor desensitization) over 4 weeks 1.

DAC vs. No-DAC: Pharmacokinetic Comparison

The clinical distinction between CJC-1295 DAC and CJC-1295 without DAC (often sold as "modified GRF 1-29" or "mod GRF") centers entirely on pharmacokinetics. The receptor pharmacology is identical.

Half-Life Difference

CJC-1295 DAC achieves a 200- to 300-fold extension in functional half-life compared to the no-DAC form. Modified GRF 1-29 has a half-life of roughly 30 minutes, consistent with other unprotected GHRH analogs like sermorelin 7. The DAC form persists for nearly a week.

Dosing Frequency Implications

This half-life difference translates directly to dosing schedules. CJC-1295 DAC supports once-weekly injection. Modified GRF 1-29 requires daily or twice-daily injections, often timed before sleep or paired with a ghrelin-mimetic peptide such as ipamorelin to produce a synergistic GH pulse 3.

GH Pulsatility Profile

The no-DAC form produces a sharp, single GH pulse that mirrors the physiologic GHRH pattern. The DAC form produces lower-amplitude but sustained GH pulsatility over days. Whether sustained stimulation or acute pulsing better replicates healthy GH physiology is not settled. Some clinicians prefer the no-DAC form for this reason, arguing that episodic dosing more closely mimics the hypothalamic GHRH pulse generator 8.

Clinical Pharmacokinetic Data: What the Teichman Trial Showed

The most-cited human PK/PD study is Teichman et al. 2006, a phase I/II dose-escalation trial of CJC-1295 DAC in 33 healthy adults aged 21 to 61 1.

Single-Dose Phase

Participants received a single subcutaneous injection of CJC-1295 DAC at 30, 60, or 125 mcg/kg. Mean GH levels rose 2- to 10-fold within hours and remained elevated for 6 days. IGF-1 rose 1.5- to 3-fold and stayed elevated for 9 to 11 days. No serious adverse events were reported at these doses.

Multi-Dose Phase

A separate cohort received weekly injections of 30 or 60 mcg/kg for 4 consecutive weeks. IGF-1 levels remained stably elevated. GH trough levels increased with each dose, suggesting some degree of accumulation. Injection-site reactions were the most common adverse event (mild erythema, transient induration).

Limitations

The trial was small (N=33), short (4 weeks multi-dose), and conducted in healthy volunteers rather than GH-deficient patients. Formal compartmental PK modeling with plasma concentration-time curves of the peptide itself (not just GH/IGF-1 pharmacodynamics) was not published. This means the 5.8 to 8 day "half-life" is a pharmacodynamic estimate, not a traditional PK parameter.

Factors That Alter CJC-1295 Pharmacokinetics

Body Composition and Albumin Status

Because the DAC variant depends on albumin conjugation, patients with hypoalbuminemia (cirrhosis, nephrotic syndrome, malnutrition) may have altered distribution and shorter effective half-life. Each albumin molecule has one Cys34 thiol, and in conditions where oxidized or glycated albumin predominates (such as poorly controlled diabetes), conjugation efficiency could theoretically decrease 9.

Age-Related Changes

Older adults have reduced GH secretory capacity at the pituitary level and lower circulating albumin. The Teichman trial included participants up to age 61 and found consistent GH/IGF-1 responses across the age range studied 1. Data in adults over 65 are not available.

Concurrent Somatostatin Tone

Somatostatin (SST) is the primary inhibitor of GH release. High somatostatin tone (e.g., from hyperglycemia, elevated free fatty acids, or exogenous octreotide) blunts the GH response to any GHRH stimulus, including CJC-1295. This is a pharmacodynamic interaction rather than a pharmacokinetic one, but it directly affects clinical outcomes 10.

Concomitant Ghrelin Mimetics

Co-administration of CJC-1295 with ghrelin receptor agonists (ipamorelin, hexarelin) is common in clinical practice. Ghrelin and GHRH act on different receptors (GHS-R1a and GHRH-R, respectively) and produce synergistic GH release. The combination does not alter the PK of either peptide, but the pharmacodynamic output (peak GH concentration) may be 2- to 5-fold higher than either agent alone 3.

Safety Signals Related to Pharmacokinetics

The prolonged half-life of CJC-1295 DAC means adverse effects, if they occur, persist for days. Reported effects in clinical studies include transient injection-site reactions, flushing, headache, and diarrhea 1. The theoretical concern with sustained GH elevation is the same as for any GH-axis stimulant: fluid retention, carpal tunnel symptoms, arthralgias, and long-term risk of insulin resistance with chronic use.

Because the drug cannot be "turned off" once injected, the no-DAC form offers a safety advantage for initial dosing or in patients with unknown GH sensitivity. A clinician can titrate the no-DAC version daily and observe the response before committing to a week-long DAC exposure.